Form 4: DexCom Director Mark Foletta Transfers Shares to Trust
Statement of Changes in Beneficial Ownership
DexCom Director Mark G. Foletta transferred 5,731 shares of common stock from direct ownership to a family trust.
Summary
- Director Mark G. Foletta executed a transfer of 5,731 shares of DexCom common stock on May 8, 2026.
- The transaction involved moving shares from direct ownership to the Mark G. and Mary E. Foletta Family Trust.
- Following the transfer, the reporting person holds 56,852 shares indirectly through the trust.
- The transaction was reported as a gift/transfer with a price of $0 per share.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine change in the legal structure of an insider's holdings rather than a market-moving transaction.
Positives
- The transaction reflects a consolidation of holdings into a family trust, which is a standard estate planning practice.
- The director maintains a significant beneficial ownership stake of 56,852 shares.
Negatives
- None identified; this is a routine internal transfer of ownership structure.
Risks
- None identified; this filing relates to internal ownership changes rather than operational or market risks.
Future Outlook
No forward-looking guidance or operational outlook provided in this filing.
Industry Context
StockSavvy.ai notes that this filing is a standard administrative disclosure regarding insider share management and does not indicate any change in the company's strategic direction or financial health.
Comparison to Industry Standards
- The filing follows standard SEC reporting requirements for directors under Section 16(a) of the Securities Exchange Act of 1934.
Related Party Transactions
- The transaction involves the transfer of shares to the Mark G. and Mary E. Foletta Family Trust, of which the reporting person is a trustee.
Stakeholder Impact
- No material impact on shareholders, employees, or customers.
Next Steps
- None identified.
Key Dates
| Date | Description |
|---|---|
| 05/08/2026 | Date of the share transfer transaction. |
| 05/11/2026 | Date the Form 4 was signed and filed. |
Keywords
DexCom, DXCM, Insider Trading, Form 4, Director, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.